Frankfurt
30.12.25 | 08:07
0,057 Euro
-25,07 % -0,019
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,068 | 0,070 | 08:29 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 05.12. | Mauna Kea Technologies: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 316 | Business Wire | Article L233-8-II of the Commercial Code
Article 223-16 of the General Regulations of the AMF
Regulatory News:
Mauna Kea Technologies (Paris:ALMKT):
Listing: Euronext Growth Paris
ISIN... ► Artikel lesen | |
| 03.12. | Mauna Kea Technologies and TaeWoong Medical USA Announce Exclusive Partnership to Accelerate Commercial Expansion in the U.S. in Pancreatic Cyst Management | 357 | Business Wire | Integrating Cellvizio into TaeWoong's portfolio of therapeutic devices to create the first fully integrated "imaging-to-therapy" solution for EUS-guided pancreatic care
Regulatory News:
Mauna... ► Artikel lesen | |
| MAUNA KEA TECHNOLOGIES Aktie jetzt für 0€ handeln | |||||
| 20.11. | Mauna Kea Technologies Receives NMPA Regulatory Approval in China for its Next-Generation Cellvizio Platform | 448 | Business Wire | NMPA approval obtained following a 3-year certification process Mauna Kea is now evaluating options to commercialize Cellvizio Gen 3 in China independently of the JV with Tasly
Regulatory... ► Artikel lesen | |
| 17.11. | XFRA 1MK: WIEDERAUFNAHME/RESUMPTION | 208 | Xetra Newsboard | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| 14.11. | Mauna Kea Technologies: €6 Million Raised To Strengthen Long Term Growth | 2 | pulse2.com | ||
| 14.11. | Mauna Kea Technologies Announces the Successful Completion of Its Financial Restructuring and €6M Capital Raise | 494 | Business Wire | 70% debt write-off, from €40M to €12M Remaining debt to be repaid over 10 years, with 90% between the end of 2029 and the end of 2035 Capital raise of €6.1M extending cash runway to the second... ► Artikel lesen | |
| 13.11. | XFRA 1MK: AUSSETZUNG/SUSPENSION | 469 | Xetra Newsboard | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILMAUNA KEA TECHNOL.EO... ► Artikel lesen | |
| 13.11. | Mauna Kea Technologies Exits Safeguard Proceedings Following Court Approval of its Plan and Initiates Minimum €5M Capital Raise | 412 | Business Wire | Safeguard plan approved by judgment of the Paris Commercial Court on November 12, 2025 Launch of a reserved capital increase in the form of shares with attached warrants (ABSA) at a price of... ► Artikel lesen | |
| 06.11. | Mauna Kea Technologies: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 309 | Business Wire | Article L233-8-II of the Commercial Code
Article 223-16 of the General Regulations of the AMF
Regulatory News:
Mauna Kea Technologies (Paris:ALMKT):
Listing: Euronext Growth Paris
ISIN... ► Artikel lesen | |
| 21.10. | Mauna Kea Technologies Announces It Has Secured Over €5M in Firm Subscription Commitments as Required for Its Capital Increase | 445 | Business Wire | New equity financing would provide the Company sufficient financial visibility to execute its strategic plan and achieve profitability The future exercise of share subscription warrants (BSA)... ► Artikel lesen | |
| 13.10. | Mauna Kea Technologies Reports Third Quarter 2025 Revenue Up +16% at Constant Exchange Rates | 276 | Business Wire | U.S. sales surge +31% at constant exchange rates, with continued acceleration over the year Commercial momentum highlighted by a doubling of U.S. system sales year-to-date Adding to U.S. commercial... ► Artikel lesen | |
| 08.10. | Mauna Kea Technologies Announces the Terms of its Financing Under its Safeguard Plan | 575 | Business Wire | Capital increase of €5m to €8m through a private placement planned for the first half of November via the issuance of shares with attached warrants (ABSA) Firm commitment from an investor for... ► Artikel lesen | |
| 06.10. | Mauna Kea Technologies Reaches a Key Milestone in Its Financial Restructuring | 939 | Business Wire | A large majority of creditors and shareholders have voted in favor of the draft safeguard plan This plan includes a 70% reduction in debt, from €40 million to €12 million, with a payment schedule... ► Artikel lesen | |
| 02.10. | Mauna Kea Technologies: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 375 | Business Wire | Article L233-8-II of the Commercial Code
Article 223-16 of the General Regulations of the AMF
Regulatory News:
Mauna Kea Technologies (Paris:ALMKT):
Listing: Euronext Growth Paris
ISIN... ► Artikel lesen | |
| 01.10. | Mauna Kea Technologies Announces 2025 Half-Year Results | 373 | Business Wire | 32% Reduction in H1 2025 Current Operating Loss excluding [Non-cash] Share-based Payments Improvement Reflects Strict Expense Control and 17% U.S. Sales Growth1 Finalization of Safeguard Plan... ► Artikel lesen | |
| 22.09. | Mauna Kea Technologies Presents the Final Terms of its Safeguard Plan | 435 | Business Wire | Reduction of the Company's debt from €40 million to €12 million, spread over 10 years Capital increase of at least €5 million post-plan adoption, with the issuance of stock warrants (BSAs) to... ► Artikel lesen | |
| 18.09. | Mauna Kea Technologies and Endotherapeutics Announce Cellvizio First Australian Orders, Advancing CellTolerance Commercial Expansion | 686 | Business Wire | Regulatory News:
Mauna Kea Technologies (Euronext Growth: ALMKT) and Endotherapeutics, today announced that Cellvizio system has been included in the Australian Register of Therapeutic Goods... ► Artikel lesen | |
| 12.09. | Mauna Kea Technologies Unveils the Outlines of its Safeguard Plan to Ensure its Turnaround | 720 | Business Wire | Shareholders, holders of securities giving access to the capital, and creditors of Mauna Kea Technologies convened into classes of affected parties to vote on the safeguard plan
Regulatory News:... ► Artikel lesen | |
| 08.09. | Mauna Kea Technologies Announces Strong Advocacy from the American Foregut Society (AFS) for Broad Reimbursement Coverage from U.S. Commercial Payors for Cellvizio | 368 | Business Wire | New letter published by the AFS highlights Cellvizio's superiority to conventional tools for detecting pre-cancerous tissue and dysplasia
Regulatory News:
Mauna Kea Technologies (Euronext... ► Artikel lesen | |
| 08.09. | Mauna Kea Technologies: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 290 | Business Wire | Article L233-8-II of the Commercial Code
Article 223-16 of the General Regulations of the AMF
Regulatory News:
Mauna Kea Technologies (Paris:ALMKT):
Listing: Euronext Growth Paris
ISIN... ► Artikel lesen |
1 2 3 Weiter >>
50 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SERNOVA BIOTHERAPEUTICS | 0,080 | +1,27 % | Sernova Biotherapeutics Closes First Tranche of a Private Placement of Equity Financing to Support Ongoing Clinical Efforts | Toronto, Ontario and Boston, Massachusetts--(Newsfile Corp. - November 13, 2025) - Sernova Biotherapeutics (TSX: SVA) (OTC: SEOVF) (FSE: PSH) ("Sernova or the Company)") a leading regenerative medicine... ► Artikel lesen | |
| FAMICORD | 5,950 | -2,46 % | EQS-News: FamiCord AG beschleunigt profitables Wachstum im dritten Quartal 2025 und stärkt Qualität und Visibilität der Umsatzentwicklung | EQS-News: FamiCord AG
/ Schlagwort(e): 9-Monatszahlen
FamiCord AG beschleunigt profitables Wachstum im dritten Quartal 2025 und stärkt Qualität und Visibilität der Umsatzentwicklung... ► Artikel lesen | |
| GERATHERM MEDICAL | 2,860 | -4,03 % | Geratherm Medical AG: Starkes Wachstum im ersten Halbjahr und operatives Break-even; KAUFEN bestätigt. | Geratherm verzeichnete im ersten Halbjahr 2025 ein starkes Wachstum: Die vergleichbaren Umsätze stiegen um 13,2 % gegenüber dem Vorjahr und sequenziell um 15,4 %. Getrieben wurde dieses Wachstum von... ► Artikel lesen | |
| PLUS THERAPEUTICS | 0,544 | -6,19 % | Plus Therapeutics Inc.: Plus Therapeutics Announces Completion of U.S. FDA Meeting on Future Clinical Development Plans for REYOBIQ in Leptomeningeal Metastases | HOUSTON, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals... ► Artikel lesen | |
| MEDICLIN | 3,580 | +0,56 % | EQS-News: MEDICLIN AG: Dr. Joachim Ramming verlässt den Vorstand der MEDICLIN AG zum Ende des Geschäftsjahres 2025 | EQS-News: MEDICLIN AG
/ Schlagwort(e): Personalie
Dr. Joachim Ramming verlässt den Vorstand der MEDICLIN AG zum Ende des Geschäftsjahres 2025
16.12.2025 / 15:00 CET/CEST
Für... ► Artikel lesen | |
| ATOSSA THERAPEUTICS | 0,568 | +2,16 % | Atossa Therapeutics Inc: Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation for (Z)-Endoxifen for Duchenne Muscular Dystrophy | Designation expands (Z)-Endoxifen program into rare pediatric neuromuscular disease and may qualify Atossa for a future Priority Review Voucher upon approval
SEATTLE... ► Artikel lesen | |
| EVOFEM BIOSCIENCES | - | - | Evofem Biosciences, Inc.: Evofem Reports Financial Results for Third Quarter of 2025, Provides Business Update | -- Increased Net Sales 10% While Lowering Operating Expenses 42% vs. Prior Year Quarter --
-- Delivered $1.0 Million of Operating Income in Q3 2025 --
SAN DIEGO... ► Artikel lesen | |
| SONOMA PHARMACEUTICALS | 2,480 | -100,00 % | Sonoma Pharmaceuticals, Inc.: National Rosacea Society Awards Seal of Acceptance to Sonoma Pharmaceuticals for Reliefacyn Advanced | BOULDER, CO / ACCESS Newswire / November 13, 2025 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous... ► Artikel lesen | |
| VERU | 2,210 | 0,00 % | Veru Inc.: Veru Reports Fiscal Year 2025 Financial Results and Clinical Program Progress | -- Following positive efficacy and safety results from Phase 2b QUALITY study, company received FDA regulatory clarity for enobosarm in combination with GLP-1 RA -- -- Incremental weight loss is an... ► Artikel lesen | |
| LIFEWARD | 0,608 | 0,00 % | Lifeward Ltd. Reports Third Quarter 2025 Financial Results | Record quarter of ReWalk systems placed for Medicare beneficiaries since fee schedule established Ongoing efficiency initiatives drive 16% year-over-year decrease in quarterly cash burn and 27%... ► Artikel lesen | |
| LIGHT AI | 0,081 | +3,59 % | Light AI Inc: Light AI president, CTO Schaller resigns | ||
| MAVEN BRANDS | 0,001 | 0,00 % | Maven Brands Inc: Maven Brands to sell subdivided Lumby land for $3.5M | ||
| EKSO BIONICS | 5,460 | 0,00 % | Applied Digital to spin out cloud business, to combine with EKSO to launch Chronoscale | ||
| SIEMENS HEALTHINEERS | 44,680 | +0,40 % | JEFFERIES stuft Siemens Healthineers auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Siemens Healthineers vor Zahlen zum ersten Geschäftsquartal auf "Buy" mit einem Kursziel von 60 Euro belassen. Der Medizintechnikkonzern... ► Artikel lesen | |
| FRESENIUS MEDICAL CARE | 40,610 | -0,25 % | EQS-CMS: Fresenius Medical Care AG: Veröffentlichung einer Kapitalmarktinformation | EQS Zulassungsfolgepflichtmitteilung: Fresenius Medical Care AG
/ Bekanntmachung nach Art. 5 Abs. 1 lit. b) der Verordnung (EU) Nr. 596/2014
Fresenius Medical Care AG: Veröffentlichung... ► Artikel lesen |
Das Unternehmen MAUNA KEA TECHNOLOGIES kann der Branche Gesundheitswesen zugeordnet werden. Der aktuelle Kurs liegt bei 0,057 Euro und damit -25,07 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MAUNA KEA TECHNOLOGIES finden Sie auf Wallstreet Online.